(no title)
gewa | 5 years ago
"To determine whether 501Y.V2 is still recognized by non-neutralizing antibodies, the binding of polyclonal sera (from Fig.2a) to a recombinant 501Y.V2 RBD+SBD1 protein and an RBD+SBD1 from the original lineage was assessed by ELISA (Fig.2b). These data revealed that binding of polyclonal plasma to 501Y.V2 RBD+SBD1 was only substantially affected in a minority of cases (14 of 44 with ≥five-fold reduction, 32%). Most of the convalescent plasma/serum suffered less than four-fold reductions in total binding activity (as measured by area under the curve), suggesting a considerable non-neutralizing antibody component are still able to bind the 501Y.V2 spike antigen"
Its also worth to note that only 44 plasma samples were used from individuals out of a population where the virus probably originated.
chemeng|5 years ago
This is correct, but just want to add that many may interpret this as a positive sign, it is not necessarily. In many cases, binding antibodies increase cell infectivity. Also, there is some research that indicates the presence of non-neutralizing antibodies without the corresponding neutralizing antibodies and humoral response may be a factor in the development of antibody dependent enhancement. As far as we know, it is the neutralization potency that strongly correlates with disease severity.
timr|5 years ago
At the very least, the current headline "strongly resistant to past immunity" is editorialized and completely misleading, and should be changed to the title of the paper.
> In many cases, binding antibodies increase cell infectivity.
Citation absolutely required. I am unaware of an example of this, let alone "many cases".